Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511459
Status:
COMPLETED
Last Update Posted:
2015-10-29
First Post:
2007-08-02
Brief Title:
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
Sponsor:
Amgen
Organization:
Amgen
Organization Data
Organization:
Amgen
Class:
INDUSTRY
Study ID:
20060341
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Amgen
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None